title: [Clinical experiences with the substitution of biosynthetic human insulin in children and adolescents with type I diabetes].
abstract: The therapeutic efficiacy of biosynthetic human insulin (BHI) is compared to that of porcine insulin into groups of 10 children each with so far untreated type I diabetes. No significant difference between the two groups could be demonstrated throughout the first months of treatment: both the initial substitution dose, and the rate of partial remission were similar. However, the regimen of the BHI treated patients had to be changed to two injections a day earlier, since BHI given subcutaneously results in a faster and shorter lasting response than porcine insulin. Thus, after 9 and 12 months of treatment a higher BHI dose than porcine insulin dose had to be given. Thirty children pretreated with regular and NPH porcine insulin, who were in the post remission period, were transferred to BHI. First, the needed dose of insulin was significantly reduced. Two to three months later, however, the need in insulin increased, so that after 9 and 12 months the original dose had to be given again. The relationship between morning (2/3) and evening (1/3) dose was constant and in the morning as well as in the evening the ratio between regular and NPH-BHI was 40%/60%. There was no significant improvement or deterioration after replacing porcine by human insulin, since both insulins have the same metabolic effects.
mesh_terms: D000293:Adolescent; D001786:Blood Glucose / Q000378:metabolism; D002648:Child; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D061389:Insulin, Regular, Pork
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007328:Insulin; D061389:Insulin, Regular, Pork; C000006:insulin, neutral
vernacular_title: Klinische Erfahrungen mit der Substitution biosynthetischen Humaninsulins bei Kindern und Jugendlichen mit Typ-I-Diabetes.